Marie Crisel E. Krupa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marie Crisel E. Krupa has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Azure Dominique Grant
People Science, Inc, Los Angeles, CA
2 shared publications Veronica Luna
People Science, Inc, Los Angeles, CA
2 shared publications- Brett Newswanger
ClostraBio, Inc., Chicago, IL, USA
1 shared publication Brian Meehan
ClostraBio, Inc., Chicago, IL, USA
1 shared publicationDavid Keller
Keller Consulting Group, Beachwood, Ohio, USA
1 shared publication- Erin Marie D. San Valentin
Department of Dermatology, Case Western Reserve University, Cleveland, OH 44106, USA
1 shared publication
Latest Publications
- Open Access
CLB101 TM Improves Gastrointestinal Symptom Burden in Overweight Adults: A Randomized, Double-Blind, Placebo-Controlled Study
Background: Anaerostipes caccae CLB101 TM is a next-generation probiotic that directly produces butyrate and is hypothesized to reduce gastrointestinal symptoms by strengthening intestinal barrier integrity. Clinical evidence for A. caccae in symptomatic adult populations remains limited. Methods: Ninety-three adults were randomized 1:1 to CLB101 TM (n=47) or placebo (n=46) for 28 days. The primary outcome was safety and tolerability as assessed by the number, frequency, and severity of adverse events. Secondary outcomes were focused on exploring signals of efficacy, and included change in the Gastrointestinal Symptom Rating Scale (GSRS) composite score from baseline to Week 4. Five GSRS subcategories were additionally evaluated. Exploratory endpoints included daily self-reported GI symptoms, as well as stool and blood measures of intestinal barrier function. Results: 71 participants were evaluated for the GSRS (77.5% female, aged 42.1 SD 12 years, BMI mean 31.3 SD 3.6). No adverse events were reported in the placebo arm, while three self-limiting adverse events were associated with CLB101 TM administration. CLB101 TM reduced GI symptom burden versus placebo on the primary GSRS composite at Week 4 (mean change: −1.60 vs −0.90; MWU p=0.040). Two secondary subscales reached significance after FDR-BH correction: Reflux (mean change: −1.26 vs −0.30; FDR-adjusted p=0.024) and Abdominal Pain (mean change: −1.86 vs −0.83; FDR-adjusted p=0.024). Daily symptom diaries showed trends toward greater reductions in abdominal discomfort, bloating, and flatulence in the active arm at the end of study. This study population did not demonstrate signs of intestinal barrier dysfunction. Product adherence averaged 97.7%. Conclusions: CLB101 TM was safe and tolerable and significantly improved overall GI symptom burden, reflux, and abdominal pain after four weeks of daily supplementation in overweight symptomatic adults. Trial Registration: The trial was approved by Sterling IRB (14583-NACraft) and registered with ClinicalTrials.gov ( NCT07336615 ).
Open AccessCLB101 TM Improves Gastrointestinal Symptom Burden in Overweight Adults: A Randomized, Double-Blind, Placebo-Controlled Study
Background: Anaerostipes caccae CLB101 TM is a next-generation probiotic that directly produces butyrate and is hypothesized to reduce gastrointestinal symptoms by strengthening intestinal barrier integrity. Clinical evidence for A. caccae in symptomatic adult populations remains limited. Methods: Ninety-three adults were randomized 1:1 to CLB101 TM (n=47) or placebo (n=46) for 28 days. The primary outcome was safety and tolerability as assessed by the number, frequency, and severity of adverse events. Secondary outcomes were focused on exploring signals of efficacy, and included change in the Gastrointestinal Symptom Rating Scale (GSRS) composite score from baseline to Week 4. Five GSRS subcategories were additionally evaluated. Exploratory endpoints included daily self-reported GI symptoms, as well as stool and blood measures of intestinal barrier function. Results: 71 participants were evaluated for the GSRS (77.5% female, aged 42.1 SD 12 years, BMI mean 31.3 SD 3.6). No adverse events were reported in the placebo arm, while three self-limiting adverse events were associated with CLB101 TM administration. CLB101 TM reduced GI symptom burden versus placebo on the primary GSRS composite at Week 4 (mean change: −1.60 vs −0.90; MWU p=0.040). Two secondary subscales reached significance after FDR-BH correction: Reflux (mean change: −1.26 vs −0.30; FDR-adjusted p=0.024) and Abdominal Pain (mean change: −1.86 vs −0.83; FDR-adjusted p=0.024). Daily symptom diaries showed trends toward greater reductions in abdominal discomfort, bloating, and flatulence in the active arm at the end of study. This study population did not demonstrate signs of intestinal barrier dysfunction. Product adherence averaged 97.7%. Conclusions: CLB101 TM was safe and tolerable and significantly improved overall GI symptom burden, reflux, and abdominal pain after four weeks of daily supplementation in overweight symptomatic adults. Trial Registration: The trial was approved by Sterling IRB (14583-NACraft) and registered with ClinicalTrials.gov ( NCT07336615 ).
- Open Access
A randomized, double□blind, placebo□controlled study evaluating the impact of Hericium erinaceus (Lion’s Mane) on cognitive performance and subjective wellbeing
Hericium erinaceus (Lion’s Mane) is a functional mushroom with a long history of culinary and traditional use, as well as potential neurotrophic and mood□modulating properties. Evidence for its effects on cognitive performance under real□world conditions, however, remains limited. In this randomized, double□blind, placebo□controlled trial, adults aged 40–75 years with self□reported cognitive difficulty completed a one□week baseline followed by eight weeks of daily supplementation with 2 g of H. erinaceus fruiting body and mycelial biomass or placebo. Cognitive performance using a computerized battery, as well as daily subjective assessments of sleep and wellbeing, were collected remotely. 109 Participants were included in the primary analysis ( H. erinaceus , n = 57; placebo, n = 52). H. erinaceus was associated with significantly greater improvement in visual attention and working memory (Juggle Factor task), subjective sleep quality, morning restedness, and mood compared with placebo ( p < 0.05). No adverse events were reported in participants receiving H. erinaceus . Together, H. erinaceus supplementation modestly improved visual attention and was associated with faster improvements in sleep quality, restedness, and mood in adults with subjective cognitive concerns.
Open AccessA randomized, double□blind, placebo□controlled study evaluating the impact of Hericium erinaceus (Lion’s Mane) on cognitive performance and subjective wellbeing
Hericium erinaceus (Lion’s Mane) is a functional mushroom with a long history of culinary and traditional use, as well as potential neurotrophic and mood□modulating properties. Evidence for its effects on cognitive performance under real□world conditions, however, remains limited. In this randomized, double□blind, placebo□controlled trial, adults aged 40–75 years with self□reported cognitive difficulty completed a one□week baseline followed by eight weeks of daily supplementation with 2 g of H. erinaceus fruiting body and mycelial biomass or placebo. Cognitive performance using a computerized battery, as well as daily subjective assessments of sleep and wellbeing, were collected remotely. 109 Participants were included in the primary analysis ( H. erinaceus , n = 57; placebo, n = 52). H. erinaceus was associated with significantly greater improvement in visual attention and working memory (Juggle Factor task), subjective sleep quality, morning restedness, and mood compared with placebo ( p < 0.05). No adverse events were reported in participants receiving H. erinaceus . Together, H. erinaceus supplementation modestly improved visual attention and was associated with faster improvements in sleep quality, restedness, and mood in adults with subjective cognitive concerns.